Deerfield Management is putting up $2bn for early-stage life sciences research through to 2030, but what does its involvement mean for its partner universities?

We certainly have come a long way since Martin Cline’s disastrous gene transfer experiment at University of California, Los Angeles ignited a public scandal forty years ago.

Cline injected recombinant DNA to treat two patients at foreign clinics with terminal hereditary blood disorders, however, the ethical debate remained in its infancy.

US guidelines explicitly forbade the experiment, although, technically, without jurisdiction over Cline’s subjects. The conservative religious lobby still had a field day and Cline was forced to resign his…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?